Advances in Heart Failure - Is It Time to Redefine Patient Selection for Sodium-Glucose Co-transporter 2 Inhibitors?

Published: 09 October 2020

  • Views:

    Views Icon 415
  • Likes:

    Heart Icon 7
  • episode_image
    Part 4 | Session 1 Q&A Discussion Martin R Cowie, Faiez Zannad, Sanjay Kaul

Overview

This educational symposium was originally broadcast as part of the ESC 2020 Digital Congress.

 

The programme focuses on summarising recent data on SGLT2 inhibitors showing reductions in CV risk, HF hospitalisations  and mortality, as well as improved quality-of-life. The expert panel also discuss how these agents should be introduced into clinical practice and contemporary heart failure guidelines for both diabetics and non-diabetics.

This independent medical education symposium was supported by a grant from the Boehringer Ingelheim & Eli Lilly and Company alliance.

Learning Objectives

  • Discuss Current SGLT2 Data and Guideline Recommendations for Utilization in Heart Failure
  • Evaluate Emerging Data on the Treatment of Heart Failure with SGLT2 Inhibitors
  • Understand the Implications of Emerging Data on the Treatment of Heart Failure With SGLT2 Inhibitors

More from this programme

Part 1

SGLT2s as a Heart Failure Drug – How Did We Get Here?

Part 2

Emerging Data SGLT2 Inhibitors in Heart Failure

Part 3

Guidelines and Practice Implications

Part 4

Q&A Discussion

Part 5

Follow-up Peer-to Peer Discussion

Faculty Biographies

Andrew JS Coats

Andrew JS Coats

Professor of Cardiology

Prof Andrew Coats is President of the Heart Failure Association and Professor of Cardiology, University of Warwick, UK. Head of Cardiology of Imperial College, London and Associate Medical Director and Director of Cardiology of the Royal Brompton and Harefield Hospitals, London. He is an Australian-British academic cardiologist as well as a successful fundraiser, university administrator and inventor. Prof Coats' main interest is heart failure.

Prof Coats is Editor-in-Chief of the Cardiac Failure Review editorial board. He has published over 20 patents and more than 650 full research papers and more than 100,000 career citations, with a personal H-index of 135. Andrew was elected to the Presidential Trio of the Heart Failure Association of the ESC in 2018 and will serve at its president 2020-2022.

From 2012 to 2017 he was Director of the Monash-Warwick Alliance, and before that…

View full profile
Faiez Zannad

Faiez Zannad

Professor of Therapeutics and Cardiology, Head of CIC

Dr Faiez Zannad is Professor of Therapeutics & Cardiology and Head of the Division of Heart Failure, Hypertension and Preventive Cardiology for the department of Cardiovascular Disease of the Academic Hospital (CHU) in Nancy and the Director of the Clinical Investigation Centre (Inserm-CHU).

Dr Zannad is currently the Chairman of the ESC Working group on Pharmacology and Drug Therapy as well as a Boardmember of the ESC Heart Failure Association. He is Past-President of the French Society of Hypertension. 

Dr Zannad is Co-Editor-in-Chief for Fundamental and Clinical Pharmacology, the official journal of the European Pharmacology Societies Federation (EUPHAR). He chairs and organises annual international meetings on CardioVascular Clinical Trials (CVCT) and on Biomarkers in Heart Failure.

View full profile